The current future understanding of inflammatory bowel disease

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 6, 2002, Pages 933-943

  Podolsky, Daniel K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Commensal bacteria; Cytokines; Genes; Innate and adaptive immunity; Leukocyte recruitment; Nod CARD; Restitution

Indexed keywords

CYTOKINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR; ANTIBIOTIC AGENT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 11; INTERLEUKIN 18 BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROBIOTIC AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; ENTERITIS; GASTROINTESTINAL MUCOSA; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; LEUKOCYTE MIGRATION; MACROPHAGE; NONHUMAN; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TISSUE REPAIR; GENETICS; IMMUNOLOGY; INTESTINE; INTESTINE MUCOSA; MICROBIOLOGY; MUCOSAL IMMUNITY; PHYSIOLOGY; REVIEW; CELL MIGRATION; CLINICAL TRIAL; CROHN DISEASE; DISEASE PREDISPOSITION; DNA MICROARRAY; DRUG EFFICACY; DRUG MECHANISM; GENETIC ASSOCIATION; HELPER CELL; HISTOPATHOLOGY; ILEITIS; INNATE IMMUNITY; INTESTINE EPITHELIUM; LAMINA PROPRIA; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; PATTERN RECOGNITION; ULCERATIVE COLITIS;

CYTOKINES; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES;

EID: 0036886298     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0354     Document Type: Article

References (36)

1. Schmitz, H, Barmeyer, C, & Fromm, M et al. (1999). Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology, 116 301-309.
2. Mashimo, H, Wu, D C, Podolsky, D K, & Fishman, M C (1996). Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science, 274 262-265.
3. Cario, E, Rosenberg, I M, & Brandwein, S L et al. (2000). Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. Journal of Immunology, 164 966-972.
4. Cario, E, & Podolsky, D K (2000). Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infection and Immunity, 68 7010-7017.
5. Podolsky, D K (2002). Inflammatory bowel disease. New England Journal of Medicine, 347(6) 417-429.
6. Fuss, I J, Neurath, M, & Boirivant, M et al. (1996). Disparate CD4+lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. Journal of Immunology, 157 1261-1270.
7. Toms, C, & Powrie, F (2001). Control of intestinal inflammation by regulatory T cells. Microbes and Infection, 3 929-935.
8. Targan, S R, Hanauer, S B, & van Deventer, S J et al. (1997). A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine, 337 1029-1035.
9. Present, D H, Rutgeerts, P, & Targan, S et al. (1999). Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine, 340 1398-1405.
10. Sandborn, W J, Feagan, B G, & Hanauer, S B et al. (2001). An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology, 120 1330-1338.
11. Stack, W A, Mann, S D, & Roy, A J (1997). Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet, 349 521-524.
12. ten Hove, T, van Montfrans, C, Peppelenbosch, M P, & van Deventer, S J (2002). Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 50 206-211.
13. Lugering, A, Schmidt, M, & Lugering, N et al. (2001). Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology, 121 1145-1157.
14. Gordon, F H, Lai, C W, & Hamilton, M I et al (2001). A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology, 121 268-274.
15. Feagan, B G, McDonald, J, & Greenberg, G R et al. (2000). An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology, 118 A874.
16. Sans, M, Salas, A, & Soriano, A et al. (2001). Differential role of selectins in experimental colitis. Gastroenterology, 120 1162-1172.
17. Hommes, D, van den Blink, B, & Plasse, T et al. (2002). Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology, 122 7-14.
18. Sands, B E, Bank, S, & Sninsky, C A et al. (1999). Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology, 117 58-64.
19. Tysk, C, Lindberg, E, Jarnerot, G, & Floderus-Myrhed, B (1988). Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut, 29 990-996.
20. Orholm, M, Munkholm, P, & Langholz, E et al. (1991). Familial occurrence of inflammatory bowel disease. New England Journal of Medicine, 324 84-88.
21. Lindberg, E, Tysk, C, Andersson, K, & Jarnerot, G (1988). Smoking and inflammatory bowel disease. A case control study. Gut, 29 352-357.
22. Andersson, R E, Olaison, G, Tysk, C, & Ekbom, A (2001). Appendectomy and protection against ulcerative colitis. New England Journal of Medicine, 344 808-814.
23. Darfeuille-Michaud, A, Neut, C, & Barnich, N (1998). Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 115 1405-1413.
24. Swidsinski, A, Ladhoff, A, & Pernthaler, A et al. (2002). Mucosal flora in inflammatory bowel disease. Gastroenterology, 122 44-54.
25. Rembacken, B J, Snelling, A M, & Hawkey, P M et al. (1999). Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet, 354 635-639.
26. Gionchetti, P, Rizzello, F, & Venturi, A et al. (2000). Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology, 119 305-309.
27. Sutherland, L, Singleton, J, & Sessions, J et al. (1991). Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut, 32 1071-1075.
28. Turunen, U M, Farkkila, M A, & Hakala, K et al. (1998). Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology, 115 1072-1078.
29. Hugot, J P, Laurent-Puig, P, & Gower-Rousseau, C et al. (1996). Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature, 379 821-823.
30. Satsangi, J, Parkes, M, & Louis, E et al. (1996). Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genetics, 14 199-202.
31. Hugot, J P, Chamaillard, M, & Zouali, H et al. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 411 599-603.
32. Ogura, Y, Bonen, D K, & Inohara, N et al. (2001). A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 411 603-606.
33. Miceli-Richard, C, Lesage, S, & Rybojad, M et al. (2001). CARD15 mutations in Blau syndrome. Nature Genetics, 29 19-20.
34. Rioux, J D, Daly, M J, & Silverberg, M S et al. (2001). Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nature Genetics, 29 223-228.
35. Cuthbert, A P, Fisher, S A, & Mirza, M M et al. (2002). The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology, 122 867-874.
36. Lesage, S, Zouali, H, & Cezard, J P et al. (2002). CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. American Journal of Human Genetics, 70 845-857.